HelloBetter offers online psychological training programs. The company offers training programs in areas, such as stress, depression, anxiety and panic, and sleep disorders. Its training programs help to reduce stress, depression, fear and panic, mood in diabetes, drink less alcohol, and brooding and worries. HelloBetter was formerly known as GET.ON Institut für Online-Gesundheitstrainings GmbH and changed its name to HelloBetter in January 2020. The company was founded in 2015 and is headquartered in Hamburg, Germany with an additional office in Berlin, Germany.
Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers. 177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, is an antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
HelloBetter offers online psychological training programs. The company offers training programs in areas, such as stress, depression, anxiety and panic, and sleep disorders. Its training programs help to reduce stress, depression, fear and panic, mood in diabetes, drink less alcohol, and brooding and worries. HelloBetter was formerly known as GET.ON Institut für Online-Gesundheitstrainings GmbH and changed its name to HelloBetter in January 2020. The company was founded in 2015 and is headquartered in Hamburg, Germany with an additional office in Berlin, Germany.
Oncorena AB develops drugs for cancer. It offers Oncorena that provides pharmacological treatment for metastasing clear cell renal cancer. The company is based in Göteborg, Sweden.
Elsa is a platform for patient driven research for better drugs, health and prevention. Elsa lets patients become their own personal researchers by providing them with a better understanding around how lifestyle factors may affect their disease activity measurements for chronic disease. To support them from a scientific perspective, Elsa gives them access to data on their specific disease (initially we work with rheumatoid arthritis) through the Riskminder foundation and scientific studies at Karolinska Institutet.
HelloBetter offers online psychological training programs. The company offers training programs in areas, such as stress, depression, anxiety and panic, and sleep disorders. Its training programs help to reduce stress, depression, fear and panic, mood in diabetes, drink less alcohol, and brooding and worries. HelloBetter was formerly known as GET.ON Institut für Online-Gesundheitstrainings GmbH and changed its name to HelloBetter in January 2020. The company was founded in 2015 and is headquartered in Hamburg, Germany with an additional office in Berlin, Germany.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
Doctrin AB operates a healthcare platform for healthcare providers who offer patients digital healthcare services. The platform is a cloud based B2B system for healthcare providers, helping the customers digitalise their patient visits. The company has a technology that replicates how doctors interview their patients. The platform is used for information gathering, decision support, and documentation services. The company was founded in 2016 and is based in Stockholm, Sweden.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.
Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
InCarda Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops transformative therapies for cardiovascular diseases that enable patients to use in the first moments of acute cardiovascular symptoms. The company develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. InCarda Therapeutics, Inc. was formerly known as Pleiades Cardio-Therapeutics, Inc. and changed its name to InCarda Therapeutics, Inc. in May 2011. The company was founded in 2009 and is based in Newark, California.
Priothera Ltd is a clinical-stage company focused on developing orally administered sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. Founded in 2020 and based in Dublin, Ireland, with an additional location in Saint Louis, France, the company seeks to improve patient outcomes by enhancing the curative potential of allogeneic hematopoietic stem cell transplantation. Its lead product, mocravimod, is designed to reduce the egress of specific T cell subsets from lymphatic tissues, thereby providing dual inhibition of graft versus host disease while promoting graft versus leukemia effects. Through this innovative approach, Priothera aims to deliver significant advancements in the treatment of patients with blood cancers.
Doctrin AB operates a healthcare platform for healthcare providers who offer patients digital healthcare services. The platform is a cloud based B2B system for healthcare providers, helping the customers digitalise their patient visits. The company has a technology that replicates how doctors interview their patients. The platform is used for information gathering, decision support, and documentation services. The company was founded in 2016 and is based in Stockholm, Sweden.
Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.
Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Aprea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cancer therapeutics that target the mutant p53 tumor suppressor protein. The lead product candidate, APR-246, is a first-in-class small molecule p53 reactivator currently in late-stage clinical development for hematologic malignancies, specifically myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006 and headquartered in Boston, Massachusetts, Aprea aims to address significant unmet medical needs in cancer treatment through innovative therapies. The company is primarily backed by KDev Investments AB and other stakeholders, including Östersjöstiftelsen and Praktikerinvest, reflecting a strong investment foundation for its research and development efforts.
Oncorena AB develops drugs for cancer. It offers Oncorena that provides pharmacological treatment for metastasing clear cell renal cancer. The company is based in Göteborg, Sweden.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
InCarda Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops transformative therapies for cardiovascular diseases that enable patients to use in the first moments of acute cardiovascular symptoms. The company develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. InCarda Therapeutics, Inc. was formerly known as Pleiades Cardio-Therapeutics, Inc. and changed its name to InCarda Therapeutics, Inc. in May 2011. The company was founded in 2009 and is based in Newark, California.
Modus Therapeutics AB, a clinical-stage drug development company, develops pharmaceutical therapies. It offers sevuparin, a drug to treat people suffering from sickle cell disease. The company was founded in 2011 and is based in Stockholm, Sweden. Modus Therapeutics AB operates as a subsidiary of Dilafor AB.
Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.
Rainier Therapeutics, Inc., a biotechnology company, develops a targeted biologic for the potential treatment of early stage and metastatic bladder cancer. It offers Vofatamab (B-701), a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) that is used for the treatment for metastatic bladder cancer. Rainier Therapeutics, Inc. was formerly known as BioClin Therapeutics, Inc. and changed its name to Rainier Therapeutics, Inc. in November 2018. The company was founded in 2010 and is based in San Leandro, California.
Doctrin AB operates a healthcare platform for healthcare providers who offer patients digital healthcare services. The platform is a cloud based B2B system for healthcare providers, helping the customers digitalise their patient visits. The company has a technology that replicates how doctors interview their patients. The platform is used for information gathering, decision support, and documentation services. The company was founded in 2016 and is based in Stockholm, Sweden.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.
Tisbury Pharmaceuticals, Inc. discovers, develops, and commercializes therapy to treat primary open angle glaucoma. The company's clinical candidate, R-801, accelerates flow via the trabecular meshwork via redox catalysis and K+-ATP (channel activation). The company was incorporated in 2017 and is based in Beverly, Massachusetts.
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases.
Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
Rainier Therapeutics, Inc., a biotechnology company, develops a targeted biologic for the potential treatment of early stage and metastatic bladder cancer. It offers Vofatamab (B-701), a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) that is used for the treatment for metastatic bladder cancer. Rainier Therapeutics, Inc. was formerly known as BioClin Therapeutics, Inc. and changed its name to Rainier Therapeutics, Inc. in November 2018. The company was founded in 2010 and is based in San Leandro, California.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders.
BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.
Aprea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cancer therapeutics that target the mutant p53 tumor suppressor protein. The lead product candidate, APR-246, is a first-in-class small molecule p53 reactivator currently in late-stage clinical development for hematologic malignancies, specifically myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006 and headquartered in Boston, Massachusetts, Aprea aims to address significant unmet medical needs in cancer treatment through innovative therapies. The company is primarily backed by KDev Investments AB and other stakeholders, including Östersjöstiftelsen and Praktikerinvest, reflecting a strong investment foundation for its research and development efforts.
Rainier Therapeutics, Inc., a biotechnology company, develops a targeted biologic for the potential treatment of early stage and metastatic bladder cancer. It offers Vofatamab (B-701), a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) that is used for the treatment for metastatic bladder cancer. Rainier Therapeutics, Inc. was formerly known as BioClin Therapeutics, Inc. and changed its name to Rainier Therapeutics, Inc. in November 2018. The company was founded in 2010 and is based in San Leandro, California.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for mitochondrial and neurodegenerative diseases affecting the eye and central nervous system. The company's lead product candidates include GS010, an AAV2-based gene therapy currently undergoing Phase III clinical trials for treating Leber hereditary optic neuropathy linked to mutations in the ND4 gene, and GS030, which is in Phase I/II trials aimed at addressing retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. In addition to these candidates, GenSight Biologics is advancing other products in preclinical stages targeting various ophthalmic and neurodegenerative conditions. The company was founded in 2012 and remains dedicated to developing innovative approaches to prevent retinal degeneration and restore vision in patients with severe vision impairment or blindness.
IDEA AG develops and commercializes non-invasive targeted therapeutics applied through the skin for delivery of drugs. The company uses Transfer some carriers for transporting the established molecular weight drugs selectively into the skin. It focuses on dermatological and pain therapeutics. The company’s Diractin is a ketoprofen in the Transfersome gel for the treatment of peripheral pain. IDEA AG was founded in 1993 and is based in Munich, Germany.
LTB4 Sweden
Venture Round in 2015
LTB4 is developing a naturally occurring molecule stimulating the innate immunity system to target diseases such as infections and cancer.
Altimmune, Inc. is a clinical stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of treatments for liver disease, immune modulation, and vaccines. The company's key product candidates include HepTcell, an immunotherapeutic for chronic hepatitis B infection, and NasoShield, an intranasal anthrax vaccine. Additionally, Altimmune is advancing NasoVAX, a recombinant intranasal vaccine, and AdCOVID, a single-dose intranasal vaccine targeting COVID-19. In the preclinical phase, it is developing ALT-801, a dual GLP-1/Glucagon receptor agonist for non-alcoholic steatohepatitis, and ALT-702, an immunostimulant for cancer treatment. Altimmune employs a proprietary non-invasive intranasal delivery technology that has demonstrated efficacy in both animal models and initial human studies. The company also engages in veterinary product development and collaborates with the University of Alabama at Birmingham to further its vaccine research.
Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.
Glionova AB is a biopharmaceutical company based in Stockholm, Sweden, focused on developing therapies for challenging cancers. Founded in 2014, the company is working on GLN-1001, an orally bioavailable small molecule designed to selectively induce cell death in glioblastoma cells while sparing normal brain tissue. This innovative approach aims to improve treatment outcomes for patients suffering from glioblastoma, a common and aggressive form of primary brain tumor. In addition to its core product development, Glionova seeks to establish strategic partnerships with global pharmaceutical companies that specialize in oncology to enhance its market presence and advance its therapeutic offerings.
Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a new treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study in Wilson Disease patients.
Rainier Therapeutics, Inc., a biotechnology company, develops a targeted biologic for the potential treatment of early stage and metastatic bladder cancer. It offers Vofatamab (B-701), a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) that is used for the treatment for metastatic bladder cancer. Rainier Therapeutics, Inc. was formerly known as BioClin Therapeutics, Inc. and changed its name to Rainier Therapeutics, Inc. in November 2018. The company was founded in 2010 and is based in San Leandro, California.
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.
BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders.
BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.
SpineVision is a spinal technology company focused on the development and marketing of implants and instrumentation for spinal treatment. The company offers spinal systems addressing a wide range of spinal pathologies including degenerative disc disease, deformity, cervical disorders, trauma and tumors. These products have been developed in collaboration with leading neurological and orthopedic surgeons which has resulted in over 20 patents.
SpineVision was founded in 1999 and is headquartered in Antony in France, with subsidiaries in Belgium, Italy, the United Kingdom, and the United States.
BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders.
BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.
Nexstim Plc is a neuromodulation company based in Helsinki, Finland, that develops and markets non-invasive brain stimulation technologies. The company specializes in image-guided transcranial magnetic stimulation (TMS) through its proprietary SmartFocus technology, which features 3D navigation for both therapeutic and diagnostic purposes. Nexstim offers the NBT system, designed to treat major depressive disorder and chronic neuropathic pain, as well as the NBS system, which is utilized for pre-surgical mapping of the brain's speech and motor cortices. Primarily, the NBS systems are sold to universities and teaching hospitals. Founded in 2000, Nexstim aims to enhance the quality of life for patients with significant unmet clinical needs through its innovative approaches to brain therapy.
Cardoz AB manufactures anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The company was founded in 2006 and is based in Stockholm, Sweden.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
FerroKin Biosciences
Series B in 2010
Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.
Oncos Therapeutics develops new cancer therapies based on its next generation oncolytic viruses. The company's unique Advanced Therapy Access Program was started in 2007 for cancer patients in whom standard-of-care therapies have failed. Today, 200 patients have undergone individually tailored oncolytic virus therapy suggesting strong safety and efficacy. The program is based on extensive scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development.
Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved. The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.
Pulmonx Corporation is a medical technology company focused on developing minimally invasive devices for diagnosing and treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company offers key products including the Zephyr Endobronchial Valve, which addresses hyperinflation in adult patients, and the Chartis Pulmonary Assessment System, a tool that evaluates collateral ventilation through flow and pressure measurements. Additionally, Pulmonx provides the StratX Lung Analysis Platform, a cloud-based service that utilizes computed tomography to analyze lung conditions, aiding in the identification of treatment targets for the Zephyr Valve. With a strong clinical foundation supported by numerous published studies, Pulmonx has received regulatory recognition, including FDA approval for its Zephyr Valve, which is now used by physicians in over 25 countries. The company aims to enhance the quality of life for emphysema patients worldwide, having facilitated the treatment of more than 19,000 patients with over 76,000 valves deployed. Founded in 1995 and headquartered in Redwood City, California, Pulmonx continues to lead in interventional procedures for COPD treatment.
FerroKin Biosciences
Venture Round in 2009
Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.
BeneChill, Inc., a medical device company, develops non-invasive cooling technologies in the United States and Europe. The company develops non-invasive cooling technologies to improve patient outcomes after acute ischemic events, such as cardiac arrest, stroke, and traumatic brain injury. Its RhinoChill System focuses on reducing patient temperature. The company was founded in 2004 and is headquartered in San Diego, California.
Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of innovative anti-infectives aimed at women's health. Founded in 2008, the company offers products such as FemiFect, an antibiotic designed to treat infections associated with vaginitis caused by bacteria, fungi, and protozoa, and SPK-601, which targets human papillomavirus (HPV) and herpes simplex virus (HSV). Lumavita markets its products through various distributors, positioning itself within the expanding biopharmaceutical sector in Switzerland. The company was previously known as Shogoo Pharmaceuticals, AG before rebranding in December 2007 and operates as a subsidiary of Shogoo Pharmaceuticals KK.
Tengion is a clinical-stage biotechnology company focused on the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Neo-Bladder Augment, which aims to assist children with neurogenic bladder resulting from spina bifida and adults with similar conditions due to spinal cord injuries. An earlier academic study on a urinary Neo-Bladder Augment was published in The Lancet in April 2006, highlighting its potential benefits. Tengion also holds an effective investigational new drug application for its Neo-Urinary Conduit and anticipates initiating a Phase 1 clinical trial for bladder cancer patients requiring bladder removal.
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors.
Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
Tengion is a clinical-stage biotechnology company focused on the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Neo-Bladder Augment, which aims to assist children with neurogenic bladder resulting from spina bifida and adults with similar conditions due to spinal cord injuries. An earlier academic study on a urinary Neo-Bladder Augment was published in The Lancet in April 2006, highlighting its potential benefits. Tengion also holds an effective investigational new drug application for its Neo-Urinary Conduit and anticipates initiating a Phase 1 clinical trial for bladder cancer patients requiring bladder removal.
Nexstim Plc is a neuromodulation company based in Helsinki, Finland, that develops and markets non-invasive brain stimulation technologies. The company specializes in image-guided transcranial magnetic stimulation (TMS) through its proprietary SmartFocus technology, which features 3D navigation for both therapeutic and diagnostic purposes. Nexstim offers the NBT system, designed to treat major depressive disorder and chronic neuropathic pain, as well as the NBS system, which is utilized for pre-surgical mapping of the brain's speech and motor cortices. Primarily, the NBS systems are sold to universities and teaching hospitals. Founded in 2000, Nexstim aims to enhance the quality of life for patients with significant unmet clinical needs through its innovative approaches to brain therapy.
Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved. The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.
OxThera AB manufactures products for the treatment of primary and secondary hyperoxaluria with bacteria and enzymes. It offers Oxabact, an orally delivered composition of live bacteria to promote the removal of endogenously produced oxalate for the treatment of primary hyperoxaluria and Oxazyme, a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase for the treatment of dietary hyperoxaluria and prevention of kidney stones. The company was founded in 2005 and is based in Stockholm, Sweden with an additional location in Knoxville, Tennessee.
CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.
BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders.
BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.
CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
Resistentia Pharmaceuticals
Series C in 2006
Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.
Tengion is a clinical-stage biotechnology company focused on the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Neo-Bladder Augment, which aims to assist children with neurogenic bladder resulting from spina bifida and adults with similar conditions due to spinal cord injuries. An earlier academic study on a urinary Neo-Bladder Augment was published in The Lancet in April 2006, highlighting its potential benefits. Tengion also holds an effective investigational new drug application for its Neo-Urinary Conduit and anticipates initiating a Phase 1 clinical trial for bladder cancer patients requiring bladder removal.
Private Equity Round in 2005
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Algeta ASA is an oncology company based in Oslo, Norway, dedicated to developing targeted therapies for cancer patients using its innovative alpha-pharmaceutical platform. The company's lead product, radium-223 dichloride, has successfully completed Phase III clinical trials for treating castration-resistant prostate cancer with bone metastases. Additionally, Algeta is advancing the development of thorium-227 conjugates, which involve linking the alpha-emitter to tumor-targeting molecules, currently in the preclinical phase. Algeta has established a collaboration with Bayer Pharma AG for the global development and commercialization of radium-223. Founded in 1997, the company originally operated under the name Anticancer Therapeutic Inventions AS before rebranding as Algeta ASA in 2003.
Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba’s technology is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, asthma/COPD and acute lung injury.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
Tengion is a clinical-stage biotechnology company focused on the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Neo-Bladder Augment, which aims to assist children with neurogenic bladder resulting from spina bifida and adults with similar conditions due to spinal cord injuries. An earlier academic study on a urinary Neo-Bladder Augment was published in The Lancet in April 2006, highlighting its potential benefits. Tengion also holds an effective investigational new drug application for its Neo-Urinary Conduit and anticipates initiating a Phase 1 clinical trial for bladder cancer patients requiring bladder removal.
OxThera AB manufactures products for the treatment of primary and secondary hyperoxaluria with bacteria and enzymes. It offers Oxabact, an orally delivered composition of live bacteria to promote the removal of endogenously produced oxalate for the treatment of primary hyperoxaluria and Oxazyme, a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase for the treatment of dietary hyperoxaluria and prevention of kidney stones. The company was founded in 2005 and is based in Stockholm, Sweden with an additional location in Knoxville, Tennessee.
CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.
- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.
Five Prime Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in the discovery and development of innovative protein therapeutics. The company is advancing several product candidates, including Bemarituzumab, an antibody targeting fibroblast growth factor receptor 2b, which is currently in Phase 3 trials for gastric and gastroesophageal junction cancers. Other candidates include FPA150, a CD8 T cell checkpoint inhibitor in Phase 1a/1b trials for various cancers, and FPT155, a soluble CD80 fusion protein aimed at enhancing T cell co-stimulation. Additionally, Cabiralizumab, which targets the colony stimulating factor-1 receptor, is being tested in Phase Ia/Ib trials in combination with Opdivo for cancer treatment. Five Prime also has BMS-986258, an anti-TIGIT antibody in Phase 1/2 trials. The company employs a unique ProScreen Engine that enables efficient production and screening of therapeutic proteins, allowing for a more comprehensive approach than traditional methods. Five Prime has established collaborations and licensing agreements with several prominent pharmaceutical companies, enhancing its research capabilities and market reach.
Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.
Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors.
Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.
Nucleonics
Series B in 2004
Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
BioStratum Incorporated develops therapeutic targets and drug candidates for preventing and treating kidney diseases, cancer, and autoimmune diseases. It offers Pyridorin, a small molecule drug candidate to treat diabetic kidney disease; and Angiocol, an anti-angiogenesis drug candidate that inhibits the growth of tumors in animal models of cancer. The company’s research pipeline includes Nephrin, a molecular target for the treatment of proteinuria; and diabetic nephropathy susceptibility genes. BioStratum Incorporated was founded in 1994 and is headquartered in Durham, North Carolina.
Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.
Bionaut Pharmaceuticals is a biotechnology company that discovers and advances small molecule drug candidates. The company’s Sentinel Pathway Reporter System has product driven applications, such as initiation and development of drug discovery programs, identifying biomarkers for clinical trials, validating existing drug candidates for a specific disease pathway, and identifying new indications for existing drug candidates and known drugs; and research-driven applications, including deciphering pathways and their relationships, and identifying genes. Bionaut Pharmaceuticals was founded in 2000 and is based in Cambridge, Massachusetts.
Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.
Orexo is a pharmaceutical company focused on developing specialized drugs and innovative treatments by leveraging known substances and proprietary technologies. The company operates primarily in the United States and Sweden, with a significant portion of its revenue stemming from its USA Pharma segment, which involves the commercialization of fully owned pharmaceuticals in the U.S. market. Orexo also explores Digital Therapeutics, offering evidence-based digital solutions that are currently in early development stages. Additionally, its headquarters in Uppsala, Sweden, oversees the research and development of new pharmaceutical products, contributing to Orexo's goal of delivering effective treatments at reduced costs and risks in a shorter timeframe.
Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.
Renovo is a biopharmaceutical product company and is a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. We aim to be first to market with a scar reduction pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need. Our pipeline includes one drug in phase 3 clinical development, two drugs in phase 2 clinical development and numerous pre-clinical candidates.
Direct Conversion AB specializes in the research, development, manufacturing, and marketing of advanced X-ray imaging sensors that utilize photon counting and hybridized semiconductor technology. Its products cater to various sectors, including dental, medical, welding, food, security, and industrial applications. The company offers a range of photon counting products under the XCounter brand, including the XC-Hydra, XC-Thor, XC-TDI, and XC-Actaeon series. Additionally, it provides charge integrating detectors under the AJAT brand, featuring models such as SNAP 225 and ARISTO. Direct Conversion also develops cadmium telluride direct conversion detectors. Founded in 1997 and headquartered in Danderyd, Sweden, the company operates additional offices in London, Espoo, and Munich. In December 2016, it changed its name from XCounter AB to Direct Conversion AB and is currently a subsidiary of Varex Imaging Corporation.
Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases.
Gyros is the world leader in automated micro-immunoassays for therapeutic protein development. Gyrolab, the company's automated and open platform, is a versatile analytical tool that dramatically reduces the time required to optimize and execute immunoassays. Time for assay optimization is often cut from weeks, to a matter of days. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. The ease of assay transfer is unsurpassed in the industry.